Oral allopregnanolone for FXTAS to be tested in PureTech’s Phase 2 trial

PureTech Health is planning a Phase 2 clinical trial to test its lead therapeutic candidate LYT-300 — an oral formulation of allopregnanolone — in people with fragile X-associated tremor/ataxia syndrome (FXTAS). The company has been awarded a grant of up to $11.4 million from the U.S. Department of Defense…

UC Davis Offers Program for Intellectually Disabled

Applications are being accepted for an innovative new four-year college program at the University of California, Davis (UC Davis) for students with intellectual disabilities such as fragile X syndrome. The program is said to be the first of its kind in California and is a collaboration of…